Evaluation of Potential Therapeutic Options for COVID-19.
作者信息
Austin Daren, Okour Malek
机构信息
Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline Research & Development, Collegeville, Pennsylvania, USA.
出版信息
J Clin Pharmacol. 2020 Aug;60(8):976-977. doi: 10.1002/jcph.1669. Epub 2020 Jul 8.
Abstract
摘要
相似文献
1
Evaluation of Potential Therapeutic Options for COVID-19.新型冠状病毒肺炎潜在治疗方案的评估
J Clin Pharmacol. 2020 Aug;60(8):976-977. doi: 10.1002/jcph.1669. Epub 2020 Jul 8.
2
COVID-19 therapeutic options for patients with kidney disease.针对肾病患者的COVID-19治疗方案。
Kidney Int. 2020 Jun;97(6):1297-1298. doi: 10.1016/j.kint.2020.03.015. Epub 2020 Mar 30.
3
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
4
Investigating hypothiocyanite against SARS-CoV-2.研究次硫氰酸盐对新型冠状病毒的作用。
Int J Hyg Environ Health. 2020 Jun;227:113520. doi: 10.1016/j.ijheh.2020.113520. Epub 2020 Apr 6.
5
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
6
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
7
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
8
Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
9
Famotidine Against SARS-CoV2: A Hope or Hype?法莫替丁对新型冠状病毒2：希望还是炒作？
Mayo Clin Proc. 2020 Aug;95(8):1797-1799. doi: 10.1016/j.mayocp.2020.05.027. Epub 2020 Jun 6.
10
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
引用本文的文献
1
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.COVID-19 的吸入疗法：药物、制剂和装置的考虑因素。
Int J Pharm. 2022 Aug 25;624:122042. doi: 10.1016/j.ijpharm.2022.122042. Epub 2022 Jul 20.
2
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
本文引用的文献
1
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.从 FDA 批准药物中鉴定抗 SARS-CoV-2 的抗病毒候选药物。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00819-20.
2
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
3
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
4
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
5
Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.氯喹和青蒿素类联合治疗与伯氨喹的药代动力学/药效学。
Malar J. 2019 Sep 23;18(1):325. doi: 10.1186/s12936-019-2950-4.
6
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.尼氯硝唑联合恩扎卢胺治疗去势抵抗性前列腺癌的 I 期研究。
PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018.
7
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.JIKI试验中埃博拉感染患者的法匹拉韦药代动力学显示浓度低于目标值。
PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.
8
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.羟氯喹的药代动力学及其在间日疟原虫所致疟疾化学预防中的临床意义
Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75. doi: 10.1128/AAC.00339-08. Epub 2009 Feb 2.
9
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.健康成年受试者中递增高剂量伊维菌素的安全性、耐受性和药代动力学。
J Clin Pharmacol. 2002 Oct;42(10):1122-33. doi: 10.1177/009127002401382731.
10
The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.新型抗疱疹药物喷昔洛韦（BRL 39,123A）静脉输注健康受试者后的耐受性及药代动力学。
Eur J Clin Pharmacol. 1992;43(5):513-6. doi: 10.1007/BF02285093.
Zotero 插件